This website is a resource intended for New Zealand healthcare professionals who are interested in information on Foundation Medicine®. If you are a New Zealand consumer, click here. These sites are not intended to provide medical advice and/or treatment guidance.  

This site is produced by Roche as a partner of Roche Foundation Medicine.


Thank you for visiting our site.

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control the content of any linked websites and if you click OK, you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet. Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Click OK to continue.

Our portfolio

High-quality portfolio

A portfolio of extensively validated comprehensive profiling services to guide treatment and research decisions at optimal times beneficial to your patients' journeys

Foundation Medicine's portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions at optimal times beneficial to your patients' journeys:1-8
Solid tumourHaematologic malignancy andsarcomaWhattype of tumour does your patient have?Tissue sampleBlood sampleTissue-based test for solid tumours1,2Liquid biopsy test for solid tumours4,5Test for haematological malignancies and sarcomas7,8
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

All of Foundation Medicine's services use our leading comprehensive genomic profiling approach, which broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients' treatment options.1,2,4,5,7-13
Genomic database


As our understanding of cancer evolves, so do our tests

Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights, such as validation of novel targets and pathways, discovery of biomarkers to stratify patients and informing trial design.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. FoundationOne CDx Technical Information (FDA Label). Available at: (Accessed May 2021).
  3. FoundationOne®CDx FDA Approval, 2017. Available at: (Accessed August 2020).
  4. Data on file: FoundationOne Liquid CDx Technical Specifications, 2020.
  5. Woodhouse et al. (2020) Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE 15(9): e0237802.
  6. FoundationOne Liquid CDx FDA Approval, 2020. Available at: (Accessed August 2020).
  7. FoundationOne®Heme Technical Specifications, 2017. Available at: (Accessed August 2020).
  8. He J et alBlood 2016; 127: 3004–3014.
  9. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  10. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  11. Ross JS et al. Cancer 2016; 122: 2654–2662.
  12. Suh JH et al. Oncologist 2016; 21: 684–691.
  13. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  14. Foundation Insights. Available at: (Accessed August 2020).